Response of different organs of immune system of mice upon administration bacterial CpG DNA

Experimental Oncology

Volumn 27, Issue 4, 2005, Pages 290-297

  Olishevsky, S ^a   Shlyakhovenko, V ^a   Kozak, V ^a   Yanish, Y ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Aseptic peritonitis; Bacillus subtilis culture medium; Bacterial CpG DNA; Hyperplasia; Immune system cells; Lymphoid organs; Organ indices; Splenomegaly; Zeta potential

Indexed keywords

BACTERIAL DNA; CPG OLIGODEOXYNUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACILLUS SUBTILIS; BACTERIUM CULTURE; CONTROLLED STUDY; CPG ISLAND; CULTURE MEDIUM; FEMALE; IMMUNE SYSTEM; IMMUNOMODULATION; LEWIS CARCINOMA; LUNG CARCINOMA; LYMPH FOLLICLE; LYMPH NODE HYPERPLASIA; LYMPHOCYTE; LYMPHOID TISSUE; MALE; METASTASIS; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PERITONITIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; SPLEEN; SPLENOMEGALY; THYMUS; ZETA POTENTIAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACILLUS SUBTILIS; CARCINOMA, LEWIS LUNG; DNA, BACTERIAL; FEMALE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; LYMPH NODES; LYMPHOCYTES; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; SPLEEN; THYMUS GLAND;

EID: 31344473943     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Plescia OJ, Braun W. Nucleic acids as antigens. Adv Immunol 1967; 6: 231-43.
2. Krieg AM. An innate immunity defense mechanism based on the recognition of CpG motifs in microbial DNA. J Lab Clin Med 1996; 128: 128-33.
3. Pisetsky DS. The immunologic properties of DNA. J Immunol 1996; 156: 421-3.
4. Bird AP. CpG islands as gene markers in the vertebrate nucleus. Trends Genet 1987; 3: 342-7.
5. Schwartz DA, Quinn TJ, Thorne PS, Sayeed S, Yi A-K, Krieg AM. CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J Clin Invest 1997; 100: 68-73.
6. Stacey KJ, Young GR, Clark F, Sester DP, Roberts TL, Naik S, Sweet MJ, Hume DA. The molecular basis forthe lack of immunostimulatory activity of vertebrate DNA. J Immunol 2003; 170: 3614-20.
7. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interpheron gamma. Proc Natl Acad Sci USA 1996; 93: 2879-83.
8. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
9. Ashkar AA, Rosenthal KL. Toll-like receptor9, CpG DNA and innate immunity. Curr Mol Med 2002; 2: 545-56.
10. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol 2005; 17: 338-44.
11. Häcker G, Redecke V, Häcker H. Activation of the immune system by bacterial CpG DNA. Immunology 2002; 105: 245-51.
12. Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004; 199: 201-16.
13. Dalpke A, Zimmermann S, Heeg K. CpG DNA in the prevention and treatment of infections. BioDrugs 2002; 16: 419-31.
14. Lazarczyk M, Grzela K, Grzela T. Immunostimulatory oligonucleotides in therapy of allergic diseases. Expert Opin Biol Ther 2005; 5: 525-36.
15. Broide D, Schwarze J, Tighe H, Gifford T, Nguyen MD, Malek S, Van Uden J, Martin-Orozco E, Gelfand EW, Raz E. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998; 161: 7054-62.
16. Carpentier AF, Auf G, Delattre JY. CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma. Frontiers Biosci 2003; 8: 115-27.
17. Olishevsky SV, Kozak W, Vanish YV, Shlyakhovenko VA. Immunostimmulatory CpG DNA in cancer vaccinotherapy. Exp Oncol 2003; 25: 83-92.
18. Shlyakhovenko VA, Olishevsky SV, Kozak W, Vanish YV, Rybalko SL. Anticancer and immunostimulatory effects of nucleoprotein fraction of Bacillus subtilis 7025 culture medium filtrate. Exp Oncol 2003; 25: 119-23.
19. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004; 6: 88-95.
20. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3: 849-54.
21. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nature Rev 2004; 4: 1-10.
22. Carpentier AF. Cancer immunotherapy with CpG-ODN. Med Sci (Paris) 2005; 21: 73-7 (In French).
23. Zatula DG. Experimental and clinical results of application of antitumor vaccines obtained by means of bacterial metabolism. Neoplasma 1984; 31: 65-74.
24. Potebnya GP, Zagadartchuk NL, Savtsova ZD, Lytvinenko OO. Antitumor activity of vaccines developed on the basis Bacillus mesentericus AB-56 culture medium filtrate or AB-56 antibiotic. Clin Surg 1998; 1: 37-48 (In Ukrainian).
25. Potebnya GP, Semernikov VA, Lisovenko GS, Khutornoy SV, Tarasova TA. Antitumor activity of vaccines obtained from tumor cell membranes and Bacillus mesentericus AB-56 metabilism products. Exp Oncol 1998; 20: 143-7 (In Russian).
26. Shlyakhovenko VO, Mosienko VS, Kozak W, Vanish Yu V, Olishevsky SV, Mazur OV, Artamonova AB. Anti-cancer vaccine on the basis of glycopeptides isolated from tumor cells. Onkologya 2004; 6: 180-4 (In Ukrainian).
27. Mazur OV, Shlyakhovenko VO, Rozumenko VD, Glavatsky AY, Lisiany NL. Changes in the immune status caused by the application of glycopeptide tumor autovaccine in a combined treatment of brain cancer. Onkologya 2004; 6: 185-8 (In Ukrainian).
28. Olishevsky S, Kozak V, Vanish Yu, Potebnya G, Lisovenko G, Olexienko I, Mazur O, Rybalko S, Shlyakhovenko V. Characteristics of extracellular DNA containing unmethylated CpG motifs isolated from Bacillus subtilis culture medium filtrate. Exp Oncol 2004; 26: 265-70.
29. The nucleic acids protocols handbook. R. Rapley, ed. Humana Press, 2000. 1072 p.
30. Calabrese KS, Paradela ASRC, Zaverucha do Valle T, Tedesco RC, Silva S, Mortara RA, Goncalves da Costa SC. Study of acute chagasic mice under immunosuppressive therapy by cyclosporin A: modulation and confocal analysis of inflammatory reaction. Immunopharmacol 2000; 47: 1-11.
31. nd edition, 1998. 115 p.
32. Jensen GL. Electrophoresis of cells. In: Immunological methods, C. Primel, ed. Moskow: Mir, 1979:195-208 (In Russian).
33. Boguslavsky LI. Bioelectrical phenomenons and phase boundary. Nauka, 1978. 360 p (In Russian).
34. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol 1999; 73: 329-68.
35. Lipford GB, Sparwasser T, Zimmermann S, Heeg K, Wagner H. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol 2000; 165: 1228-35.
36. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol 1997; 27: 2340-4.
37. Staber FG, Metcalf D. Cellular and molecular basis of the increased splenic hemopoiesis in mice treated with bacterial cell wall components. Proc Natl Acad Sci USA 1980; 77: 4322-5.
38. Lipford GB, Sparwasser T, Bauer M, Zimmerman S, Koch ES, Heeg K, Wagner H. Immunostimulatory DNA: sequence-dependent production of potentially harmfull or useful cytokines. Eur J Immunol 1997; 27: 3420-6.
39. Sparwasser T, Hültner L, Koch ES, Luz A, Lipford GB, Wagner H. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary hemopoiesis. J Immunol 1999; 162: 2368-74.
40. Yu D, Kandimalla ER, Bhagat L, Tang J-Y, Cong Y, Tang J, Agrawal S. "Immunomers" -novel 3′-3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Research 2002; 30: 4460-9.
41. Kandimalla ER, Bhagat L, Zhu F-G, Yu D, Cong Y, Wang D, Tang JX, Tang J-Y, Knetter CF, Lien E, Agrawal S. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. PNAS 2003; 100: 14303-8.
42. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-9.
43. Davila E, Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 2000; 165: 539-47.
44. Weeratna RD, McCluskie MJ, Xu Y, Davis HL. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000; 18: 1755-62.
45. Farman CA, Kornbrust DJ. Oligodeoxynucleotide studies in primates: antisense and immune stimulatory indications. Toxicologic Pathol 2003; 31: 119-22.
46. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, Zinkernagel R, Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG Oligodeoxynucleotide administration. Nat Med 2004; 10: 187-92.
47. Kuznecov VA. Recognition of target cells by NK cells unaided specific NK-receptors. Biophisical model. Immunologiya 1992; 3: 8-13 (In Russian).
48. Silva FFC, Santos AB, de Carvalho TM, de Souza W. Surface charge of resident, elicited, and activated mouse peritoneal macrophages. J Leukoc Biol 1987; 41: 143-9.